Protagenic TherapeuticsPTIX
13F holders, Q1 2024 (March 31)11holders
$22.45avg. 13F price*
At the end of Q1 2024, 11 institutions reported holding Protagenic Therapeutics Inc. (PTIX) in their 13F filings. The largest holders were Eagle Asset Management Inc. ($11.9M), Vanguard Group Inc. ($58K) and Geode Capital Management, LLC ($44K).
- Company
- Protagenic Therapeutics Inc.
- CUSIP
- 74365N202
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $11.9M |
| Exits | 1 | $12K |
Ownership 11 holders
| Eagle Asset Management Inc. | 0.06% | New | 419,324 | $11.9M |
| Vanguard Group Inc. | 0.00% | No change | 33,166 | $58K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.1% | 25,174 | $44K |
| Osaic Holdings, Inc. | 0.00% | New | 21,414 | $37K |
| FNY Investment Advisers, LLC | 0.02% | No change | 18,750 | $32K |
| State Street Corp. | 0.00% | No change | 13,812 | $24K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -35.6% | 5,813 | $10K |
| Wells Fargo & Company | 0.00% | Add +3.9% | 27 | $47 |
| Bank of America Corp. | 0.00% | No change | 1 | $2 |
| Morgan Stanley | 0.00% | No change | 1 | $2 |
| Cwm, LLC | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is PTIX's weight in each manager's 13F, not the share of Protagenic Therapeutics Inc. the manager owns.